keyword
MENU ▼
Read by QxMD icon Read
search

Ribavirin

keyword
https://www.readbyqxmd.com/read/29777934/specific-stability-indicating-spectrofluorimetric-method-for-determination-of-ledipasvir-in-the-presence-of-its-confirmed-degradation-products-application-in-human-plasma
#1
Ramadan Ali, Adel A Marzouk, Reda A Abdelhameid, Mahmoud A Omar
A rapid and specific spectrofluorimetric method with higher sensitivity was developed for determination of ledipasvir (LDS) in tablets and human plasma. The proposed method relies on hydrogen bonding formations between the hydroxyl groups of polyoxyethylene 50 stearate and LDS, causing significant enhancement of its native fluorescence. The fluorescence intensity was measured at 430 nm after excitation at 340 nm. The fluorescence-concentration plot was rectilinear over the range 1-400 ng mL-1 with detection and quantification limits of 0...
May 16, 2018: Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy
https://www.readbyqxmd.com/read/29773440/case-report-identification-of-recombinant-hcv-genotype-1b-2b-by-viral-sequencing-in-two-patients-with-treatment-failure-who-responded-to-re-treatment-with-sofosbuvir-and-daclatasvir
#2
Luis Antonio Uribe-Noguez, Alicia Ocaña-Mondragón, José Antonio Mata-Marín, Allison Cázares-Cortázar, Rosa María Ribas-Aparicio, María Elena Gómez-Torres, Jesus Gaytán-Martínez, María de la Luz Martínez-Rodríguez
Hepatitis C virus (HCV) infection is a global health problem. HCV has been classified into seven genotypes and >67 subtypes. Genotyping is necessary to enable selection of appropriate treatments. The commercial molecular techniques currently used do not identify some HCV subtypes, mixed infections and recombinant forms. In this study, the core-E1 and NS5B regions were sequenced and phylogenetically analysed to identify infections by HCV recombinant genotype 1b-2b in two patients who had initially been diagnosed with HCV genotype 2 infection by reverse hybridization with a Versant HCV Genotype 2...
May 15, 2018: Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy
https://www.readbyqxmd.com/read/29773081/long-term-familial-mediterranean-fever-remission-on-successful-hepatitis-c-virus-treatment-in-a-patient-not-responding-to-colchicine-a-case-report
#3
Manik Gemilyan, Gagik Hakobyan, Susanna Ananyan
BACKGROUND: Familial Mediterranean fever is an autosomal recessive disorder characterized by periodic febrile attacks of aseptic serositis and/or arthritis. The main treatment is colchicine which prevents attacks in the majority of patients except for a group of colchicine-resistant cases. Chronic hepatitis C is a viral infection causing chronic inflammation of liver tissue (hepatitis) which ultimately progresses to fibrosis and liver cirrhosis with a high chance of hepatocellular carcinoma...
May 18, 2018: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/29768546/first-wave-protease-inhibitors-for-hepatitis-c-genotype-1-treatment-a-real-life-experience-in-brazilian-patients
#4
Silvana Gama Florencio Chachá, João Paulo Vilela Rodrigues, Roberta Chaves Araújo, Leonardo Régis Leira Pereira, Márcia Guimarães Villanova, Fernanda Fernandes Souza, Rodrigo de Carvalho Santana, Ana de Lourdes Candolo Martinelli
INTRODUCTION: Licensed for chronic hepatitis C treatment in 2011, the protease inhibitors (PIs) telaprevir (TVR) and boceprevir (BOC), which have high sustained viral responses (SVR), ushered a new era characterized by the development of direct-action drugs against the hepatitis C virus (HCV). The aim of this study was to analyze the effectiveness and safety of BOC and TVR administered with pegylated interferon and ribavirin and to share the experience of a Brazilian reference center...
March 2018: Revista da Sociedade Brasileira de Medicina Tropical
https://www.readbyqxmd.com/read/29765256/grazoprevir-elbasvir-for-the-treatment-of-adults-with-chronic-hepatitis-c-a-short-review-on-the-clinical-evidence-and-place-in-therapy
#5
REVIEW
Nimisha Sulejmani, Syed-Mohammed Jafri
Chronic hepatitis C virus (HCV) infection impacts approximately 71 million people and approximately 400,000 deaths are attributed to HCV-related liver disease annually worldwide. Mainstay of treatment for over 25 years has been pegylated interferon until the advent of protease inhibitors, which has led to all-oral HCV treatment regimens that have changed the outlook of hepatitis C treatment. Grazoprevir/elbasvir provides high rates of efficacy and tolerability and is an all-oral once daily treatment option for HCV infection...
2018: Hepatic Medicine: Evidence and Research
https://www.readbyqxmd.com/read/29762684/effective-treatment-of-experimental-lymphocytic-choriomeningitis-virus-infection-consideration-of-favipiravir-for-use-with-infected-organ-transplant-recipients
#6
Brady T Hickerson, Jonna B Westover, Kie-Hoon Jung, Takashi Komeno, Yousuke Furuta, Brian B Gowen
Lymphocytic choriomeningitis virus (LCMV) poses a substantial risk to immunocompromised individuals. The case fatality rate in recent clusters of LCMV infection in immunosuppressed organ transplantation recipients has exceeded 70%. In the present study, we demonstrate potent antiviral activity of favipiravir against acute, disseminated LCMV infection in NZB mice. Treatment resulted in complete protection against mortality and dramatic reductions in viral loads. In contrast, ribavirin, the current antiviral of choice, was mostly ineffective...
May 14, 2018: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29762255/ombitasvir-paritaprevir-ritonavir-dasabuvir-ribavirin-for-chronic-hepatitis-c-virus-genotype-1b-infected-cirrhotics-turquoise-iv
#7
Vasily Isakov, Dzmitry Paduta, Rolando M Viani, Jeffrey V Enejosa, Viktor Pasechnikov, Olga Znoyko, Pavel Ogurtsov, Pavel O Bogomolov, Marina V Maevskaya, Xiaotian Chen, Nancy S Shulman
OBJECTIVE: An estimated 336 per 100 000 people in Russia are infected with hepatitis C virus, including up to 75% with genotype (GT) 1b. In the TURQUOISE-II/-III trials, a 12-week regimen of the direct-acting antiviral agents ombitasvir (OBV), paritaprevir (PTV), ritonavir, and dasabuvir (DSV) in GT1b-infected patients with compensated cirrhosis resulted in 12-week sustained virologic response (SVR) rates of 100%. PATIENTS AND METHODS: In TURQUOISE-IV, GT1b-infected patients (n=36) from Russia and Belarus with compensated cirrhosis, who were treatment naive or previously treated with pegylated interferon/ribavirin (RBV), received OBV/PTV/ritonavir+DSV+RBV for 12 weeks...
May 14, 2018: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29759922/treatment-with-ribavirin-of-acute-hepatitis-and-severe-renal-damage-in-an-immunocompetent-patient
#8
Raquel Ríos León, Miguel Angel Rodríguez Gandía, Enrique Rodríguez de Santiago, Eugenia Sánchez Rodríguez, Antonio Guerrero García, Alvaro Flores de Miguel, María Teresa Tenorio Cañamás, Agustín Albillos Martínez
No abstract text is available yet for this article.
May 11, 2018: Gastroenterología y Hepatología
https://www.readbyqxmd.com/read/29754329/efficacy-and-safety-of-sofosbuvir-plus-daclatasvir-with-or-without-ribavirin-large-real-life-results-of-patients-with-chronic-hepatitis-c-genotype-4
#9
Adel Abdel-Moneim, Alaa Aboud, Mohamed Abdel-Gabaar, Mohamed I Zanaty, Mohamed Ramadan
BACKGROUND AND AIM: Clinical studies evaluating the efficacy of daclatasvir (DCV) for treatment of chronic hepatitis C virus (HCV) genotype 4 (GT4) infection are scarce. This study aims to evaluate the efficacy and safety of DCV plus sofosbuvir (SOF) with or without ribavirin (RBV) for treatment of Egyptian patients infected with HCV GT4. METHODS: Between April 2016 and March of 2017, a large cohort of 946 patients with chronic HCV GT4 was enrolled for completing the treatment...
May 12, 2018: Hepatology International
https://www.readbyqxmd.com/read/29753376/effectiveness-of-sofosbuvir-ribavirin-and-peg-ifn%C3%AE-2a-in-the-treatment-of-na%C3%A3-ve-egyptian-patients-with-chronic-hepatitis-c-virus-genotype-4
#10
Fatma Abdallah, Gehad Mohamed, Mohsen Ibrahim, Mokhtar El Tarabily
BACKGROUND: Egypt is one of the largest epidemic areas of hepatitis C virus (HCV) in the world. Its prevalent genotype is 4 with a majority of subtype 4a. In 2013, the Food and Drug Administration approved a new direct-acting antiviral drug (sofosbuvir) to treat patients with chronic HCV infection. In Egypt, the patients are already being treated with sofosbuvir in conjunction with ribavirin and pegylated interferon alfa-2a (PEG-IFNα-2a) for 12 weeks since 2015. The present study was planned to explain the efficacy of this treatment regimen against the HCV genotype 4a in Egyptian patients and its pretreatment predictive factors of virological response...
May 2018: American Journal of the Medical Sciences
https://www.readbyqxmd.com/read/29751499/survival-and-prognostic-factors-in-mixed-cryoglobulinemia-data-from-246-cases
#11
Cesare Mazzaro, Luigino Dal Maso, Endri Mauro, Valter Gattei, Michela Ghersetti, Pietro Bulian, Giulia Moratelli, Gabriele Grassi, Francesca Zorat, Gabriele Pozzato
INTRODUCTION: The clinical and therapeutic management of mixed cryoglobulinemia (MC) remains a subject of controversy. In addition, most studies have not recorded the long-term follow-up and the outcome of these cases. MATERIAL AND METHODS: We enrolled 246 patients affected by MC who were consecutively admitted to our Department from January 1993 to February 2013. Clinical and biological data had been recorded until June 2014. RESULTS: The median age (at diagnosis) was 60 years (range 26⁻83)...
May 3, 2018: Diseases (Basel)
https://www.readbyqxmd.com/read/29750037/simple-score-to-predict-risk-of-hepatocellular-carcinoma-in-chronic-hepatitis-c-patients-with-advanced-fibrosis-after-pegylated-interferon-and-ribavirin-therapy
#12
Ching-Chih Hu, Cheng-Hao Weng, Liang-Che Chang, Chih-Lang Lin, Yen-Ting Chen, Ching-Fang Hu, Man-Chin Hua, Li-Wei Chen, Rong-Nan Chien
Purpose: Eradication of chronic hepatitis C virus (HCV) after interferon-based therapy and its association with the reduction of risk of hepatocellular carcinoma (HCC) in HCV-infected patients with advanced fibrosis is controversial. The study is aimed to develop a simple scoring model for HCC prediction among advanced fibrotic chronic hepatitis C (CHC) patients after pegylated interferon (pegIFN) and ribavirin (RBV) therapy. Patients and methods: We enrolled 271 biopsy-proven CHC patients with advanced fibrosis between 2003 and 2016, and divided them into non-HCC (n=211) and HCC (n=60) groups...
2018: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/29746648/effects-of-sofosbuvir-based-hepatitis-c-treatment-on-the-pharmacokinetics-of-tenofovir-in-hiv-hcv-coinfected-individuals-receiving-tenofovir-disoproxil-fumarate
#13
Christine E MacBrayne, Kristen M Marks, Daniel S Fierer, Susanna Naggie, Raymond T Chung, Michael D Hughes, Arthur Y Kim, Marion G Peters, Diana M Brainard, Sharon M Seifert, Jose R Castillo-Mancilla, Lane R Bushman, Peter L Anderson, Jennifer J Kiser
Background: The nucleotide analogues tenofovir and sofosbuvir are considered to have low potential for drug interactions. Objectives: To determine the effect of sofosbuvir-based HCV treatment on plasma concentrations of tenofovir and cellular concentrations of tenofovir diphosphate. Methods: HIV-infected participants with acute HCV were treated for 12 weeks with sofosbuvir + ribavirin in Cohort 1 or 8 weeks with ledipasvir/sofosbuvir in Cohort 2 of AIDS Clinical Trials Group study 5327...
May 9, 2018: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/29743792/effect-of-sofosbuvir-plus-daclatasvir-in-hepatitis-c-virus-genotype-4-patients-promising-effect-on-liver-fibrosis
#14
Asmaa M Abdel-Aziz, Mohamed A Ibrahim, Azza A El-Sheikh, Maha Y Kamel, Nagwa M Zenhom, Salam Abdel-Raheim, Hisham Abdelhaleem
Background/purpose: The effect of sofosbuvir and daclatasvir in treatment of genotype 4 Hepatitis C Virus (HCV) is not well documented. This study investigated the safety and efficacy of sofosbuvir plus daclatasvir with or without ribavirin in treatment of HCV genotype 4 patients. The impact of therapy on liver fibrosis as well as the role of IL18 polymorphism in therapeutic outcome was assessed. Methods: One hundred HCV genotype 4 patients were categorized into 2 groups...
March 2018: Journal of Clinical and Experimental Hepatology
https://www.readbyqxmd.com/read/29743791/impact-of-direct-acting-antiviral-therapy-for-treatment-of-hepatitis-c-genotypes-1-3-and-4-a-real-life-experience-from-india
#15
Varun Mehta, Ramit Mahajan, Vandana Midha, Vikram Narang, Kirandeep Kaur, Arshdeep Singh, Anand Malhotra, Aslam Parvez, Ajit Sood
Objective: To assess impact of Direct Acting Antiviral (DAA) therapies for treatment of Hepatitis C Virus (HCV) genotypes 1, 3 and 4 in a real-world cohort from India. Methods: Adults with chronic HCV infection treated with Sofosbuvir (SOF) and Ledipasvir (LDV) (genotypes 1 and 4) or SOF and Daclatasvir (DCV) (genotype 3), with or without Ribavirin (RBV) between December 2015 and December 2016 were included. The primary endpoint was Sustained Virological Response at Post-treatment Week 12 (SVR12)...
March 2018: Journal of Clinical and Experimental Hepatology
https://www.readbyqxmd.com/read/29743773/first-reported-case-of-respiratory-syncytial-virus-infection-causing-guillain-barr%C3%A3-syndrome
#16
Scott A Helgeson, Alexander J Heckman, Dana M Harris
Acute immune-mediated polyneuropathies are a group of illnesses that cause paralysis following an infection. We describe a case of one of these illnesses being caused by the respiratory syncytial virus (RSV). An 81-year-old female was admitted for an RSV infection. She went into respiratory failure requiring intubation and mechanical ventilation and treatment with ribavirin. When she was extubated, she had bilateral lower extremity weakness and absent reflexes. Her disease progressed rapidly to involve her diaphragm, and eventually, the family agreed to let the natural death process occur...
April 2018: Indian Journal of Critical Care Medicine
https://www.readbyqxmd.com/read/29742470/real-life-efficacy-of-ledipasvir-sofosbuvir-in-hepatitis-c-genotype-4-infected-patients-with-advanced-liver-fibrosis-and-decompensated-cirrhosis-%C3%A2-%C3%A2-%C3%A2
#17
Faisal M Sanai, Ibrahim H Altraif, Khalid Alswat, Adnan AlZanbagi, Mohamed A Babatin, Abdallah AlMousa, Nawaf H Almutairi, Mohammed S Aljawad, Abdullah S Alghamdi, Abdulrahman A Aljumah, Abduljaleel M Alalwan, Waleed K Al-Hamoudi, Abdullah M Assiri, Yaser Dahlan, Ashwaq Alsahafi, Hammad S Alothmani, Mohammed S AlSaleemi, Waleed A Mousa, Ali Albenmousa, Abdelrahman Awny, Haziz Albiladi, Ayman A Abdo, Hamdan AlGhamdi
Limited clinical trial data has shown high efficacy of co-formulated ledipasvir/sofosbuvir (LDV/SOF) in the treatment of hepatitis C virus (HCV) genotype (GT)-4 infected cirrhotic patients. We assessed real-world safety and efficacy of LDV/SOF with or without ribavirin (RBV) in GT4-infected patients with compensated and decompensated cirrhosis. PATIENTS & METHODS: This observational cohort (n=213) included GT4 treatment-naïve (59.6%) and -experienced (40.4%) patients with advanced fibrosis (F3, Metavir; n=30), compensated (F4, n=135) and decompensated cirrhosis (n=48) treated for 12 (n=202) or 24 weeks (n=11) with LDV/SOF...
May 6, 2018: Journal of Infection
https://www.readbyqxmd.com/read/29741370/design-synthesis-antiviral-bioactivity-and-defense-mechanisms-of-novel-dithioacetal-derivatives-bearing-a-strobilurin-moiety
#18
Jin Chen, Jing Shi, Lu Yu, Dengyue Liu, Xiuhai Gan, Song Baoan, De-Yu Hu
A series of dithioacetal derivatives bearing a strobilurin moiety were designed and synthesized on the basis of our previous work. The antiviral activities of these compounds against Potato virus Y (PVY), Cucumber mosaic virus (CMV), and Tobacco mosaic virus (TMV) were systematically evaluated. Bioassay results indicated that C14 elicited excellent curative and protective activities against PVY, CMV, and TMV. The former had 50% effective concentrations (EC50) of 125.3, 108.9, and 181.7 μg/mL, respectively, and the latter had 148...
May 9, 2018: Journal of Agricultural and Food Chemistry
https://www.readbyqxmd.com/read/29740528/treatment-with-sofosbuvir-and-daclatasvir-with-or-without-ribavirin-improves-patient-reported-outcomes-in-hepatitis-c
#19
Lucas Pereira Jorge de Medeiros, Mario Barreto Correa Lima, Marcia Maria Amêndola Pires, Alessandra Mendonça Almeida Maciel, Renata Barboza Vianna Medeiros, Mariana Dermínio Donadel, Isabela Martins Becattini Pereira, Fábio Marchon Leão, Luiz Eduardo Amorim Correa Lima Pires, Helio Rzetelna, Carlos Eduardo Brandão-Mello
Objectives: To evaluate the impact of 3 treatment regimens upon health-related quality of life and work productivity using patient-reported outcomes (PROs) in chronic hepatitis C infected patients: sofosbuvir (SOF) + daclatasvir (DCV); SOF + DCV + ribavirin (RBV); SOF + simeprevir (SMV). Methods: 4 questionnaires were used to evaluate PROs before, during and after treatment: Short Form-36 (SF-36), Chronic Liver Disease Questionnaire (CLDQ) - hepatitis C virus (HCV), Work Productivity and Activity Index, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)...
April 2018: Osong Public Health and Research Perspectives
https://www.readbyqxmd.com/read/29735803/the-observed-effect-of-gastric-bypass-surgery-on-direct-acting-antiviral-treatment-a-case-report
#20
Elise J Smolders, Sophie B Willemse, Omar El-Sherif, Saye Khoo, David M Burger
Chronic hepatitis C virus (HCV) infection can be cured with treatment using direct-acting antivirals (DAAs). Although these drugs have been widely studied, information about certain special populations is missing. In this case report we describe a treatment-experienced patient with chronic HCV infection genotype 1b, treated with 150 mg/day simeprevir, 400 mg/day sofosbuvir, and 1,000 mg/ day ribavirin for 24 weeks, after a Roux-and-Y gastric bypass. At steady-state a pharmacokinetic curve was recorded of sofosbuvir, GS-331007, and simeprevir...
April 9, 2018: Annals of Hepatology
keyword
keyword
29712
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"